Interaction between vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells and alpha 4 integrins on leukocytes is thought to mediate the selective recruitment of eosinophils and lymphocytes that occurs in allergic diseases. IL-4 is associated with allergic conditions, and it has been shown to selectively increase expression of VCAM-1 on endothelial cells in vivo, suggesting that it could be responsible for VCAM-1 expression in allergic disease. Using a combination of immunofluorescence, flow cytometry, and Northern analysis, we compared the effect of TNF-alpha and IL-4 on VCAM-1 expression. TNF-alpha is also associated with allergic diseases, and it rapidly increases transcription of the VCAM-1 gene. The effect of IL-4 was relatively modest with prolonged kinetics: VCAM-1 was not detected until 72 h after treatment with IL-4. However, when TNF-alpha and IL-4 were combined, there was a synergistic increase in VCAM-1 expression and a dramatic prolongation of the appearance of VCAM-1 on the cell surface. This synergy results from a combination of transcriptional activation by TNF-alpha and the stabilization of resulting transcripts by IL-4. We propose that IL-4 allows subthreshold concentrations of TNF-alpha (concentrations that would not normally activate expression of adhesion molecules on the endothelium) to selectively increase VCAM-1 expression and to prolong its appearance on the surface of cells in allergic disease. 
Introduction
Adhesion of leukocytes to the endothelium is mediated by several classes of cell adhesion molecules (1, 2) . E-selectin (CD62E) interacts with oligosaccharide containing molecules on leukocytes mediating the initial rolling of the leukocyte in the slower moving circulation of the microvasculature (3, 4) . This interaction allows the strong adhesion mediated by members of the Ig superfamily, including vascular cell adhesion molecule-I (VCAM-1 1, INCAM-1 10, CD106) and intercellular adhesion molecule-I (ICAM-1, CD54), which interact with integrins, a family of heterodimeric receptors on the leukocyte surface ( 1, 2) . These same molecules have also been implicated in the subsequent transmigration across the endothelium. Many of the endothelial surface cell adhesion molecules, including Eselectin, VCAM-l, and ICAM-l, are increased by inflammatory cytokines, such as TNF-a, IL-I, and LPS (1, 2) .
The differential expression and activation of cell adhesion molecules have been postulated to account for the selective recruitment of leukocytes seen in different inflammatory diseases (1, 2) . For example, infiltrates containing neutrophils are characteristic of bacterial infections, whereas infiltrates of eosinophils and lymphocytes typify allergiclike conditions such as atopic dermatitis, allergic rhinitis, and allergic asthma (5) .
Two integrins, a4,i1 (CD49d/CD29) and a4/37, are present on a subpopulation of leukocytes, including lymphocytes and eosinophils but not neutrophils. The a4 integrins bind VCAM-1 but not ICAM-1 or E-selectin (6, 7) . The interaction between VCAM-I and a4 integrins has been shown to mediate the adhesion of lymphocytes and eosinophils but not neutrophils to endothelial cells in culture, suggesting that the interaction between VCAM-I and a4 integrins could mediate a selective recruitment of leukocyte subpopulations in vivo ( 1, 2) .
In support of this possibility, several reports have demonstrated a correlation between VCAM-1 expression and the selective recruitment of lymphocytes and eosinophils in vivo (8) . For example, VCAM-I has been identified on the endothelium in correlation with the lymphocytic infiltration seen in the rejection process after human heart, liver, and pancreas allograft transplantation (9, 10) . VCAM-1 has been identified on the endothelium in perennial allergic rhinitis where there is a selective infiltrate of eosinophils (11) . In a recent report, VCAM-I/a4 integrin interactions mediated recruitment of lymphocytes and eosinophils to the trachea in an inhaled antigen mouse model of asthma (12) . In this model inhalation of ovalbumin in sensitized mice resulted in the expression of VCAM-1 but not ICAM-I on tracheal endothelium; this expression of VCAM-1 correlated with infiltration of T cells and eosinophils. Infusion of blocking antibodies to VCAM-I or a4 but not ICAM or Eselectin prevented the antigen-induced infiltration of T cells and eosinophils, resulting in peripheral blood eosinophilia. In another study, VCAM-1 was upregulated on the endothelium of bronchial biopsies taken from asthmatic patients after bronchial antigen provocation. The intensity and extent of VCAM-1 expression correlated with the eosinophilic infiltrate (13) . Together these studies suggest that VCAM-l expression is selec-tively upregulated on the endothelium and its expression correlates with the selective recruitment of lymphocytes and eosinophils.
This selective upregulation of VCAM-1 expression may involve the cytokine, IL-4. IL-4 is found at sites of allergic inflammation. Increased levels of IL-4 have been found in the blood and bronchoalveolar lavage (BAL) of allergic asthmatic patients ( 14) . Increased IL-4 mRNA was found in T cells recovered from the BAL of allergic asthmatics (15) . In a study of allergen-provoked rhinitis in hay fever sufferers, tissue eosinophilia in nasal biopsies correlated with CD4+ Th2 cells expressing IL-4 mRNA (16) . Together, these studies suggest a role for IL-4 in allergic conditions. Additionally, experimental evidence suggests a role for IL-4 in the selective recruitment of leukocytes. In a mouse model of allergic asthma, IL-4 was detected in the BAL in association with a lymphocytic and eosinophilic pulmonary infiltrate (17) . When IL-4-deficient mice (IL-4 -/-) and wild-type mice (IL-4 + / + ) were sensitized and then treated with ovalbumin, there was a substantial attenuation of the BAL eosinophilia and the selective peribronchial inflammation in the IL-4 -/-mice compared with the wild-type mice (18) . In nude mice injected with IL-4 either intraperitoneally or intradermally, there was a marked increase in recruitment of eosinophils but not neutrophils ( 19) . Likewise, overexpression of IL-4 in transgenic mice resulted in allergic-like inflammatory disease with the selective recruitment of eosinophils and mononuclear cells (20) .
Originally, IL-4 was thought to be restricted to lymphocytes; however, it is now clear that other cells also secrete IL-4 (21). For example, enhanced release of IL-4 has been measured in human mast cells from asthmatics (22) . The mast cell is positioned among microvascular endothelium in the skin, gut, and lung, in a location ideally suited for antigen presentation and a subsequent inflammatory response (21) . Likewise, human basophils, which are also thought to be important cellular components in allergic inflammation, reportedly secrete IL-4 (21).
IL-4 has been shown to increase the adhesiveness of endothelial cells for leukocytes that express a4 integrins (23) (24) (25) . This increased adhesiveness results from an IL-4-mediated selective upregulation of VCAM-1 expression on the endothelial cell surface and is not mediated by an interaction with ICAM-1 or E-selectin (26) (27) (28) (29) (30) . Therefore, IL-4 could be responsible, at least in part, for the selective increase in VCAM-1 expression at sites of allergic inflammation, resulting in the selective recruitment of the subset of leukocytes that express a4 integrins.
IL-4 has also been shown to act with TNF-a to selectively increase VCAM-1 expression in cultured endothelial cells (25, 28, 31 ) . Likewise, in a baboon model of acute dermal microvascular inflammatory response, subcutaneously administered IL-4 combined with low doses of TNF-a resulted in a selective recruitment of lymphocytes. In this model there was increased expression of VCAM-1, but neither ICAM-1 nor E-selectin were detected on high endothelial venules (32) . Interestingly, increased TNF-a has also been detected in asthmatic patients (33, 34) , raising the possibility that TNF-a and IL-4 could mediate selective recruitment of lymphocytes and eosinophils through the synergistic upregulation of VCAM-1 expression on the endothelium. Immunofluorescence andflow cytometry. Mouse anti -human monoclonal antibodies BBA-5 (R&D, diluted 1:1000), BBA-2 (R&D, diluted 1:1000), and LB2 (diluted 1:1000, Dr. E. A. Clark, Seattle, WA) all from a 1-mg/ml stock were used to detect human VCAM-1, E-selectin, and ICAM-1, respectively. Rabbit anti-human polyclonal antibodies NF-KB p50 (NLS), NF-KB p65 (A), NF-KB p52 (K27), relB (C19), and c-rel (C) were used to detect the NF-KB/Rel family of transcription factors (Santa Cruz Biotechnology, Santa Cruz, CA, diluted 1:500 from a 1-mg/ml stock). Immunofluorescent labeling was done as described (46) except cells were fixed with methanol at -20°C for 6 min and 1% Teleostean gelatin (Sigma Chemical Co., St. Louis, MO) was used as a nonspecific blocking agent. Single color flow cytometry using an Epics Elite flow cytometer (Coulter Cytometry, Hialeah, FL) was done as described (47) . Initial gating was done using forward and side scatter to eliminate debris and identify a uniform population of endothelial cells. For each sample . I x I04 previously gated events were analyzed.
RNA analysis. Total mRNA was isolated using RNASTAT-60 (TelTest "B", Inc., Friendswood, TX) and subjected to Northern blot analysis. Probes for VCAM-1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNAs were described previously (46 Results IL-4 alone induces only a low level of VCAM-1 expression with delayed kinetics. As a first step in examining the mechanism of action of IL-4 on VCAM-1 expression, we examined the time course of IL-4-mediated induction of VCAM-1 expression by immunofluorescent labeling in HUVECs. Surprisingly, we saw no evidence of VCAM-1 expression until 72 h after treatment with IL-4 and the level of expression appeared to be substantially less than with TNF-a (Fig. 1) . IL-4 was used from three sources and HUVECs were obtained from several donors. Our results indicate that IL-4 alone had only a limited effect on VCAM-1 expression and the kinetics of its induction were delayed compared with TNF-a.
TNF-a and IL-4 act synergistically to increase VCAM-1 expression. It has been demonstrated that combining IL-4 with TNF-a increases VCAM-1 expression (25, 28, 31) . Here, we show clear synergy between TNF-a and IL-4. When the concentration of TNF-a was reduced from 10 to 0.2 ng/ml, there was little or no apparent immunolabeling for VCAM-1 on permeabilized HUVECs (Fig. 2) . Likewise, treatment with IL-4 at 100 U/ml for 24 h did not increase the expression of VCAM-1. However, when IL-4 was combined with TNF-a at 0.2 ng/ml, VCAM-1 expression increased dramatically. This synergistic expression appeared to be significantly greater than with TNFa alone at 10 ng/ml.
To quantitate surface immunofluorescence, HUVECs were analyzed by flow cytometry. The results show that in response to 10 ng/ml of TNF-a, VCAM-1 expression peaks at 24 h after treatment and is significantly decreased after 72 h ( (Fig. 3) . Therefore, 11L-4 not only acts to increase the level of VCAM-1, it also affects the kinetics of expression, prolonging the presence of VCAM-1 on the cell surface. In contrast to the effect of 11L4 on VCAM-I expression, IL-4 had no effect, either alone or in combination with TNF-a, on the expression of ICAM-1 or E-selectin after 10, 24, or 72 h of cytokine treatment (Fig. 4 and results not shown). TNF-a and IL-4 synergistically upregulate VCAM-1 mRNA. Northern blot analysis was used to determine whether the com- bination of TNF-a and IL-4 increases the expression of VCAM-1 at the level of the mRNA. VCAM-I mRNA was not detected in untreated HUVECs (Fig. 5) . However, treatment of HUVECs with 10 and 0.2 ng/ml of TNF-a alone for 16 h resulted in a cytokine concentration-dependent increase in VCAM-l mRNA. Treatment with either 100 or 2,000 U/ml of IL-4 alone for 16 h resulted in only a trace of VCAM-I mRNA. When IL-4 was added along with TNF-a, there was a synergistic increase in the level of VCAM-l mRNA. These results with VCAM-I mRNA parallel those observed with the protein, indicating that TNF-a and IL-4 act at the level of VCAM-I mRNA. The electrophoretic mobility of all cytokine-induced VCAM-I mRNA was the same, suggesting that the form of VCAM-l mRNA produced in response to the cytokines is similar.
The addition ofIL4 along with TNF-a results in persistence of VCAM-I mRNA. Treatment of HUVECs with TNF-a alone resulted in a peak of VCAM-I mRNA at 8 h that diminished by 48 h (Fig. 6) . Similar results were seen with ICAM-1 (which lacks a promoter), respectively, were transfected into confluent HUVECs (49). The cells were treated with cytokines as indicated for 16 h before harvesting. TNF-a was added at two concentrations, 10 (H) and 0.2 (L) ng/ml. IL-4 was added at 100 U/ml. Similar results were seen with IL-4 at 2,000 U/ml (results not shown).
region of the human VCAM-1 gene promoter) confers the proper tissue specificity and is responsive to TNF-a in transfection assays (49). In HUVECs, the activity of 2180VCAMCAT is not above background in the absence of cytokines. Treatment with TNF-a results in activation of this construct, which is mediated by two adjacent NF-kB-like sites at positions -63 and -77 bp of the VCAM-1 gene. As was the case with VCAM-1 mRNA, IL-4 alone had little or no effect on VCAM-l gene promoter activity (Fig. 7) . In contrast, TNF-a significantly increased VCAM-1 gene promoter activity, as we demonstrated previously (49). When combined with TNF-a, IL-4 had only a slight effect on promoter activity. Since IL-4 alone had no effect, it was possible that IL-4 acts to facilitate the activity of TNF-a. One mechanism through which this could occur is by increasing the level of the NF-KB proteins or by facilitating their translocation to the nucleus. In a series of immunolabeling experiments using antibodies to NF-KB/Rel family members, we observed translocation of p65 to the nucleus after treatment with TNF-a, constitutive nuclear expression of p50 and RelB, and constitutive cytosolic expression of c-rel as described previously (results not shown) (50, 51 (Fig. 5) , the difference in half-lives between TNF-a and the combination of TNF-a and IL-4 was examined. The half-life for VCAM-I mRNA after TNF-a treatment was 5 h (Fig. 8) . This contrasts to the markedly prolonged half-life seen when TNF-a and IL-4 were used in combination. As controls, TNF-a and IL-4 had no significant effect on the half-life of GAPDH mRNA and IL-4 had no effect on the half-life of ICAM-1 mRNA induced in response to TNF-a ( Fig. 5 and results It will eventually be interesting to determine whether there is any relationship between the mechanism of IL-4-mediated mRNA stabilization in endothelial cells and the IL-4-mediated mechanism of mRNA destabilization in leukocytes.
